Novartis, Pear co-develop digital therapeutics for MS and schizophrenia
Executive Summary
Novartis AG and Pear Therapeutics Inc. are together developing candidates from Pear's prescription digital therapeutics pipeline for applications in multiple sclerosis and schizophrenia.
Deal Industry
- Digital Health
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice